Candel Therapeutics Inc

NASDAQ:CADL  
9.98
-0.34 (-3.30%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)286.31M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.01 Million
Adjusted EPS-$0.31
See more estimates
10-Day MA$10.39
50-Day MA$10.37
200-Day MAN/A
See more pivots

Candel Therapeutics Inc Stock, NASDAQ:CADL

117 Kendrick Street, Suite 450, Needham, Massachusetts 02494
United States of America
Phone: +1.617.916.5445
Number of Employees:

Description

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.